HIV感染者HAART中LEP、HCY的变化及临床意义

doi:10.16088/j.issn.1001-6600.2015.03.021

Abstract

Abstract: The content of Leptin (LEP) and homocysteine (HCY) of cardiovascular diseases (CVD) markers in HIV infected patients was detected in Highly active antiretroviral therapy (HAART) process and the effect on prevention of CVD in HIV infected patients was determined to provide a basis for early prevention in HIV infection complicated with CVD. Methods: Serum samples obtained from 30 healthy subjects and 62 HIV infected patients(28 treatment nalve and 34 treatment experienced patients) were analyzed by enzyme-linked immunosorbent assay (ELISA) to determine the HCY and LEP contents.The Results show that the level of serum HCY in HIV infected treatment group was obviously higher than that of untreated group and normal control group (P<0.01).There was no marked difference of the LEP level between the three controls(P>0.05). Serum HCY and CD4⁺T lymphocyte count, treatment time and TG were positively correlated (P<0.01). Dynamically detecting the level of HCY and LEP may be beneficial to the early prevention of HIV infection complicated with CVD.

Key words: HIV, HAART, cardiovascular disease, homocysteine, leptin

CLC Number:

R512.91

LI Hai-li, KONG Yan-lin, ZHANG Shuai, HU Ting-ting, JIANG Qian, LI He-wei, JIANG Jiu-xi, LI Lin. Clinical Significance of Changes of LEP and HCY Levels in Serum of HIV-infected Patients Receiving Highly Active Antiretroviral Therapy[J].Journal of Guangxi Normal University(Natural Science Edition), 2015, 33(3): 138-143.

References

[1] FORD E S, GREENWALD J H, RICHTERMAN A G, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection[J]. AIDS, 2010, 24(10): 1509-1517.
[2] CURRIER J S, LUNDGREN J D, CARR A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy[J]. Circulation, 2008, 118(2): e29-35.
[3] TRIANT V A, LEE H, HADIGAN C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease[J]. J Clin Endocrinol Metab, 2007, 92(7): 2506-2512.
[4] ANUURAD E, SEMRAD A, BERGLUND L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease[J]. Metab Syndr Relat Disord, 2009, 7(5): 401-410.
[5] LIEB W, SULLIVAN L M, HARRIS T B, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals[J]. Diabetes Care, 2009, 32(4): 612-616.
[6] REEDER S J, HOFFMANN R L, MAGDIC K S, et al. Homocysteine: the latest risk factor for heart disease[J]. Dimens Crit Care Nurs, 2000, 19(1): 22-28.
[7] SACKOFF J E, HANNA D B, PFEIFFER M R, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City[J]. Ann Intern Med, 2006, 145(6): 397-406.
[8] AHIMA R S, LAZAR M A. Adipokines and the peripheral and neural control of energy balance[J]. Mol Endocrinol, 2008, 22(5): 1023-1031.
[9] DE ROSA V, PROCACCINI C, CALI G, et al. A key role of leptin in the control of regulatory T cell proliferation[J]. Immunity, 2007, 26(2): 241-255.
[10] STEINER A A, ROMANOVSKY A A. Leptin: at the crossroads of energy balance and systemic inflammation[J]. Prog Lipid Res, 2007, 46(2): 89-107.
[11] SANCHEZ-POZO C, RODRIGUEZ-BANO J, DOMINGUEZ-CASTELLANO A, et al. Leptin stimulates the oxidative burst in control monocytes but attenuates the oxidative burst in monocytes from HIV-infected patients[J]. Clin Exp Immunol, 2003, 134(3): 464-469.
[12] PASTERNAK R C, GRUNDY S M, LEVY D, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease[J]. J Am Coll Cardiol, 1996, 27(5): 978-990.
[13] GUARALDI G, VENTURA P, GARLASSI E, et al. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease[J]. HIV Med, 2009, 10(1): 28-34.
[14] UCCELLI M C, TORTI C, LAPADULA G, et al. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART[J]. Ann Nutr Metab, 2006, 50(3): 247-252.
[15] CORIA-RAMIREZ E, CISNEROS L N, TREVINO-PEREZ S, et al. Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1-infected patients[J]. J Acquir Immune Defic Syndr, 2010, 54(5): 477-481.
[16] LIOTTA A, MAGGIO M C, DI C P, et al. Serum leptin and interleukin-6 levels in pediatric patients with HIV[J]. J Pediatr Endocrinol Metab, 2003, 16(2): 179-183.
[17] CARR A, SAMARAS K, THORISDOTTIR A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study[J]. Lancet, 1999, 353(9170): 2093-2099.
[18] SHEVITZ A, WANKE C A, FALUTZ J, et al. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update[J]. AIDS, 2001, 15(15): 1917-1930.
[19] AL-FADHLI M, SARAYA M, QASEM J, et al. Relationship between leptin levels and suppressed CD4 counts in HIV patients[J]. Med Princ Pract, 2013, 22(1): 54-58.
[20] MATARESE G, CASTELLI-GATTINARA G, CANCRINI C, et al. Serum leptin and CD4⁺T lymphocytes in HIV+ children during highly active antiretroviral therapy[J]. Clin Endocrinol (Oxf), 2002, 57(5): 643-646.
[21] NETO M G, ZWIRTES R, BRITES C. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management[J]. Braz J Infect Dis, 2013, 17(6): 691-700.
[22] FRIIS-MOLLER N, WEBER R, REISS P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from the DAD study[J]. AIDS, 2003, 17(8): 1179-1193.
[23] STANLEY T L, GRINSPOON S K. Body composition and metabolic changes in HIV-infected patients[J]. J Infect Dis,2012,205 (S3): S383-390.
[24] UMARANI V, MUVVALA S, RAMESH A, et al. Rutin potentially attenuates fluoride induced oxidative stress mediated cardiotoxicity, blood toxicity and dyslipidemia in rats[J]. Toxicol Mech Methods, 2015, 25(2): 143-149.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Clinical Significance of Changes of LEP and HCY Levels in Serum of HIV-infected Patients Receiving Highly Active Antiretroviral Therapy

PDF (PC)

Abstract

Cite this article

share this article

References

Related Articles 2

Metrics

Comments

Recommended 0

[1]	KONG Yan-lin, ZHANG Shuai, WANG Xue-wen, LI He-wei, HU Ting-ting, JIANG Qian, JIANG Jiu-xi, PAN Ding-quan, ZHANG Zhen-kai, LI Lin, SUN Chang-rong, LI Jing-yun, LIANG Hao, LIANG Bing-yu. Epidemiology and Gene Analysis of HIV-1 in Guangxi,China [J]. Journal of Guangxi Normal University(Natural Science Edition), 2015, 33(1): 127-133.
[2]	HUANG Jia-qing, ZHANG Ying, JIANG Jiu-xi, HU Ting-ting, LI He-wei, ZENG Si-en, XU Ru, SHEN Jian-feng, XIE Fu-jing. Clinical Significance of Changes of Interleuking-18 and Interleuking-18 Binding Protein Levels in Serum of HIV-infected Patients [J]. Journal of Guangxi Normal University(Natural Science Edition), 2012, 30(4): 110-114.